|Positive WB detected in||A431 cells|
|Positive IP detected in||HL-60 cells|
|Positive IHC detected in||human tonsillitis tissue, human renal cell carcinoma tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
10735-1-AP targets RAC2 in WB, IP, IHC,ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||RAC2 fusion protein Ag1202|
|Full Name||ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)|
|Calculated molecular weight||21 kDa|
|Observed molecular weight||21 kDa|
|GenBank accession number||BC001485|
|Gene ID (NCBI)||5880|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
RAC2, also named as GX, belongs to the small GTPase superfamily and Rho family. RAC2 is a plasma membrane-associated small GTPase which cycles between an active GTP-bound and inactive GDP-bound state. In active state binds to a variety of effector proteins to regulate cellular responses, such as secretory processes, phagocytose of apoptotic cells and epithelial cell polarization. RAC2 augments the production of reactive oxygen species (ROS) by NADPH oxidase. Defects in RAC2 are the cause of neutrophil immunodeficiency syndrome.
AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis.
J Exp Clin Cancer Res
Long noncoding RNA AFAP1-AS1 acts as a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway.
In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression.